Ann: Security Class Reinstatement to Quotation- OPTOB, page-506

Astellas acquired Iveric Bio in 2023 for almost $10bn AUD. Now that was for a dry AMD drug still pending FDA approval. Wet AMD is a more developed and larger market, and given the fact that our drug complements other procedures (doesn’t need to compete against them) and improves VA, I think people here are being quite conservative with their estimates, this may open around $3 after the first readout but it won’t stay that low for long, particularly not with another set of results expected to closely follow. IMO any offer would have to be closer to $10 per share, OPT indeed has a lot of ground (share price wise) still to make up for even before we reach the readouts.